The adjuvant effect of lucanthone (miracil D) in clinical radiation therapy.

Abstract

Clinical trials were undertaken to determine whether lucanthone (miracil D) affects radiation-induced regression in measurable pulmonary metastases and advanced squamous-cell oral and pharyngeal tumors. The time required for 50% tumor regression was decreased by approximately 50% in those patients who received lucanthone in addition to irradiation. These results indicate that lucanthone has a definite adjuvant effect when used together with irradiation.

• Authors: S Turner, R Bases, A Pearlman, M Nobler, B Kabakow
• Journal: Radiology (Radiology) Vol. 114 Issue 3 Pg. 729-31 (Mar 1975) ISSN: 0033-8419 [Print] United States
• PMID: 1118579 (Publication Type: Journal Article)

Chemical References

• Cobalt Radioisotopes
• Lucanthone

Topics

• Carcinoma, Squamous Cell (drug therapy, radiotherapy, therapy)
• Cobalt Radioisotopes
• Humans
• Lucanthone (therapeutic use)
• Lung Neoplasms (drug therapy, radiotherapy, therapy)
• Mouth Neoplasms (drug therapy, radiotherapy, therapy)
• Neoplasm Metastasis
• Pharyngeal Neoplasms (drug therapy, radiotherapy, therapy)
• Radioisotope Teletherapy
• Time Factors